Miltenyi Bioindustry
A Full-Service Partner for CGT

A division of Miltenyi Biotec, Miltenyi Bioindustry is a full-scale contract development and manufacturing organization (CDMO), providing customers with services for the development and manufacturing of lentiviral vectors (LVVs) and cell and gene therapy (CGT) products.

With over 30 years of experience working in the immunotherapy market, the Miltenyi group of companies understands how to meet GMP requirements to help develop and optimize clinical therapies as well as manage the range of support functions necessary to effectively manufacture CGT products at scale.

“Many CDMOs try to be all things to all people,” says Sallie Cassel, the executive vice president of marketing at Miltenyi Biotec. “They offer a wide range of services—from microbial fermentation to bioconjugates to drug products—positioning themselves as a jack of all trades with CGT services as just another option. However, Miltenyi Bioindustry is completely focused on CGT.”

As both the producer and the service provider—Miltenyi Bioindustry relies on its own instruments and reagents for each workflow step—the organization is able to control the entire supply chain and deliver greater security and planning clarity to its customers.

“Most CDMOs struggle with the aggressive timelines requested by their CGT customers, and because they work in an array of modalities, they may lack the depth of expertise that is specifically required in this rapidly growing market and struggle with a shortage of available experts needed to meet the expected time frames,” says Cassel.

“Miltenyi Bioindustry offers a unique blend of in-house experts and proven experience plus a global supply chain that is under our control from start to finish. This combination produces practical solutions and ensures that our customers can overcome obstacles and advance their work from the research phase to the commercial stage within predictable timelines.”

With products and services that give customers direct access to Miltenyi expertise, it’s easier for Miltenyi Bioindustry customers to hit their milestones quickly, without making brick-and-mortar investments, while enjoying the freedom to focus on other ventures.

Miltenyi Bioindustry positions its customers for future advancement by combining the latest cutting-edge processes with its established legacy of products/services to aid researchers who are developing new therapies. With workflows that have been built and tested over and over by its own teams and that deliver proven results, Miltenyi Bioindustry customers can focus on other critical aspects of their business rather than reinventing the wheel. In fact, nearly every currently available commercial CAR T cell therapy product on the market utilizes Miltenyi solutions.

Many companies claim to do everything. At Miltenyi, we are focused—a boutique biotech that excels in our specialty

With expansive R&D experience, an unparalleled grasp of their own technology, and a clinical trial background, the experts who make up Miltenyi Bioindustry hold a real-world understanding of what customers need at every step of their journey—from pre-clinical through commercial stages.

“We are committed to employing this knowledge to help our customers by expediting the process of getting to market, overcoming any challenges they face, and enabling them to meet their goals,” says Cassel. “Whether our customers are looking for product development support, assay optimization, LVV production, or commercial-scale manufacturing of their cell therapy product, we are here to help. Many companies claim to do everything. At Miltenyi, we are focused—a boutique biotech that excels in our specialty.”